Hikal Gujarat facility gets EIR from USFDA

Published On 2019-12-13 09:37 GMT | Update On 2019-12-13 09:37 GMT

The pharmaceutical manufacturing facility at Panoli in Gujarat was recently inspected by the US Food and Drug Administration (USFDA) in compliance with their requirements.

New Delhi: Drug firm, Hikal recently announced that the US Health regulator has issued an Establishment Inspection Report (EIR) for its facility at Panoli, Gujarat.

The pharmaceutical manufacturing facility at Panoli in Gujarat was recently inspected by the US Food and Drug Administration (USFDA) in compliance with their requirements.

The five-day detailed inspection was carried out during the period September 9-13 this year, the company said in its BSE filing.

Also Read: Hikal up 11 pc on successful USFDA inspection

The inspection confirmed the site to be compliant with the principles and guidelines of Current Good Manufacturing Practices (CGMP), it added.

The inspection concluded with 'zero' 483 observations from auditors. "The EIR received today has classified the facility under NAI (No Action Indicated) for CGMP compliance, " Hikal said.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Hikal Gujarat facility gets EIR from USFDA

Similar News